Twitter | Search | |
Chiles Research Inst
The Earle A Chiles Research Institute, a part of , is a leader in cancer immunotherapy research and innovation since 1993.
2,778
Tweets
1,275
Following
1,364
Followers
Tweets
Chiles Research Inst retweeted
Campbell 9h
So proud of our EACRI scientists and leaders.
Reply Retweet Like
Chiles Research Inst retweeted
Laural Porter 13h
A mutation that appears to be more infectious is spreading including in Oregon. Hear from viral detective and docs working on a vaccine 7pm on . .
Reply Retweet Like
Chiles Research Inst retweeted
Laural Porter 16h
Reply Retweet Like
Chiles Research Inst retweeted
R. Bryan Bell, MD, DDS, FACS Jul 9
Proud that Portland Medical Center (home to ) was ranked #7/3200+ hospitals in the U.S. by the ⁦⁩, the first Index to include such metrics as inclusivity & civic leadership in evaluating hospital performance
Reply Retweet Like
Chiles Research Inst Jul 9
Tune into 7p PT this Friday for an important conversation about the response to . Viewers will also hear from as they share the latest research and updates.
Reply Retweet Like
Chiles Research Inst Jul 9
Congrats to Dr Brian Piening () and colleagues for their work highlighted in . 'Metabolic Dynamics and Prediction of Gestational Age and Time to Delivery in Pregnant Women' >>
Reply Retweet Like
Chiles Research Inst retweeted
The Oregonian Jul 9
COVID-19 survival rate improves significantly at local hospitals
Reply Retweet Like
Chiles Research Inst retweeted
R. Bryan Bell, MD, DDS, FACS Jul 7
Ongoing Trial: EA3161 is testing maintenance immunotherapy versus observation in patients with HPV-related throat cancer - Now open ⁦⁩ ⁦⁩ ⁦⁩ ⁦⁩ ⁦
Reply Retweet Like
Chiles Research Inst retweeted
AACR Jul 8
The special session on and Cancer—chaired by Antoni Ribas—is available for viewing. Registration is now open for our Virtual Meeting on and Cancer, July 20-22. Learn more:
Reply Retweet Like
Chiles Research Inst Jul 7
'They basically saved my life': Portland cancer patient receives cutting-edge radiation treatment via
Reply Retweet Like
Chiles Research Inst retweeted
R. Bryan Bell, MD, DDS, FACS Jul 6
Reply Retweet Like
Chiles Research Inst retweeted
William Redmond Jul 6
More evidence of benefits for !!! A Phase II Single-Arm Study of Pembrolizumab With Enzalutamide in Men With Metastatic Castration-Resistant Prostate… Great collaboration between + !
Reply Retweet Like
Chiles Research Inst retweeted
AACR Jul 2
The symposium on "Health Inequities and Disparities in the COVID-19 Pandemic and Impact on Cancer Care" is available for viewing. Our Virtual Meeting on and Cancer will feature sessions on health disparities.
Reply Retweet Like
Chiles Research Inst Jul 1
Congrats to Team Science Award recipient, Dr. Brady Bernard, for his work with The Cancer Genome Atlas Project, a landmark program to catalog genetic mutations responsible for cancer, using sequencing and .
Reply Retweet Like
Chiles Research Inst retweeted
R. Bryan Bell, MD, DDS, FACS Jul 1
It’s July 1st- time for new fellows & residents! Delighted to welcome Dr. Andrew Baker as our Cancer Institute fellow in head & neck oncologic/microvascular reconstructive surgery for 2020-2022.
Reply Retweet Like
Chiles Research Inst retweeted
AACR Jun 29
Registration is now open for AACR VIRTUAL MEETING: COVID-19 AND CANCER, July 20-22. This special AACR conference will focus on the presentation of emerging data in basic, clinical, and epidemiologic research related to COVID-19 and cancer.
Reply Retweet Like
Chiles Research Inst Jun 30
speaks to about the importance of regular cancer screenings.
Reply Retweet Like
Chiles Research Inst retweeted
Ashish Patel, MD, DDS, FACS Jun 27
Congratulations to former Fellow, and my partner for publishing our TORS + risk adapted adjuvant therapy data for p16+ OPC. 91% 5-year OS with 0% PEG dependence. Proud to have contributed to this study.
Reply Retweet Like
Chiles Research Inst retweeted
R. Bryan Bell, MD, DDS, FACS Jun 27
Our institutional experience w TORS: 91% 5yr OS, 0% PEG dependence. Avoided chemo in 70%. Chemo didn’t change outcome, even in pts w ECS or +margins. >5 +LNs or low yield on ND (<18) worsened OS.
Reply Retweet Like
Chiles Research Inst retweeted
Walter J Urba MD, PhD Jun 26
Proud of Research Network response to . Since 3/6, rapid startup of 11+ trials of , convalescent plasma and other therapies at 20+ sites from AK to TX, 1000+ patients enrolled.
Reply Retweet Like